BlackRock, Inc. 13D and 13G filings for Denali Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 3:05 pm Sale |
2025-03-31 | 13G | Denali Therapeutics Inc. DNLI |
BlackRock Inc. BLK |
10,490,610 7.200% |
-3,297,263 (-23.91%) |
Filing |
| 2024-11-08 5:31 pm Unchanged |
2024-09-30 | 13G | Denali Therapeutics Inc. DNLI |
BlackRock Inc. BLK |
13,787,873 9.600% |
0 (Unchanged) |
Filing |
| 2024-10-21 4:11 pm Purchase |
2024-09-30 | 13G | Denali Therapeutics Inc. DNLI |
BlackRock Inc. BLK |
13,787,873 9.600% |
2,245,012 (+19.45%) |
Filing |
| 2024-01-25 4:59 pm Purchase |
2023-12-31 | 13G | Denali Therapeutics Inc. DNLI |
BlackRock Inc. BLK |
11,542,861 8.400% |
2,221,432 (+23.83%) |
Filing |
| 2023-01-31 5:52 pm Purchase |
2022-12-31 | 13G | Denali Therapeutics Inc. DNLI |
BlackRock Inc. BLK |
9,321,429 6.900% |
1,210,607 (+14.93%) |
Filing |
| 2022-02-03 4:41 pm Purchase |
2021-12-31 | 13G | Denali Therapeutics Inc. DNLI |
BlackRock Inc. BLK |
8,110,822 6.600% |
1,734,744 (+27.21%) |
Filing |
| 2021-02-02 2:56 pm Purchase |
2020-12-31 | 13G | Denali Therapeutics Inc. DNLI |
BlackRock Inc. BLK |
6,376,078 5.300% |
1,348,764 (+26.83%) |
Filing |